NCT05762211

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

A Multi-center Randomized, Double Blinded Phase IIb Trial Evaluating Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 387 (estimated)
• Sponsor: MaaT Pharma · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This randomized, placebo-controlled phase IIb study (PHOEBUS trial) aims to evaluate the activity of fecal microbiotherapy MaaT033 to improve survival through the prevention of transplant-related complications in eligible alloHCT patients

Conditions

• Transplant Complication

Interventions

Type	Name	Description
DRUG	Pooled allogeneic fecal microbiotherapy	Capsule for oral use
DRUG	Placebo	Capsule for oral use

Timeline

• Start date: 2023-10-31
• Primary completion: 2026-10-31
• Completion: 2027-02-15
• First posted: 2023-03-09
• Last updated: 2024-12-27

Locations

54 sites across 6 countries: Belgium, France, Germany, Netherlands, Spain, United Kingdom